News

Privigen is an immune globulin intravenous [human], 10% liquid, developed for intravenous administration in CIDP patients. CSL Behring research and development senior vice president Val Romberg said it

Randomized, double-blind study will assess ixmyelocel-T’s efficacy and safety in treating patients with advanced heart failure due to ischemic dilated cardiomyopathy. Aastrom Biosciences acting chief medical officer David

The company’s US-based distributor Covis Pharmaceuticals will promote the products, manufactured and supplied by Sanofi, in the US. Sanofi retains the rights for the products outside US. Covis

As per the deal, Aragen is developing CHO cell lines in addition to estimating the characteristics for various antibodies and protein therapeutics. Innovent CEO Michael Yu said Aragen

Ambrx will use site-specific conjugation technology in addition to proprietary linkers and payloads to produce optimized ADCs, which will then be developed and commercialized by Astellas. Agensys site

The solution is used to plan, track and report on clinical trials and is available as a hosted, software-as-a-service (SaaS) application. The Impact CTMS features improved data entry

The approval enables pharma firms that develop pain therapeutics to rely on Frontage for controlled-substance product development support services. Frontage has upgraded its units, security and personnel procedures

The new four-strain vaccine will be marketed as Influsplit Tetra in Germany and Fluarix Tetra in the UK. This is the first four-strain influenza vaccine to be approved

The phase III study is a multi-centre, multi-national study evaluating belimumab. Randomised, double-blind study is designed to asses efficacy and safety profile of belimumab as a combination therapy